Completed PHASE1 INTERVENTIONAL 3-arm NCT01683773

Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)

Sponsor: Aeras

Conditions Tuberculosis

Interventions AERAS-402 MVA85A

Updated 5 times since 2017 Last updated: Sep 16, 2014 Started: Sep 30, 2012 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01683773, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by Aeras, it has been updated 5 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aeras
Crucell Holland BV
Emergent BioSolutions
University of Birmingham
University of Oxford

Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United Kingdom
• Oxford, United Kingdom